Zhang et al. [83] have synthetized a series of novel 3,5-dimethylisoxazole derivatives as BRD4/HDAC dual inhibitors, demonstrating their antiproliferative effects on chronic myeloid leukemia (CML) and AML cell lines. This evidence concerns the gene BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive.